Drug Trial Radar · NCT02831660
CU Programme of Idarucizumab for Japanese Patients
Last checked: Nov 20, 2026Latest source record: Mar 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1
Actual
Start
Jul 22, 2016
Primary completion
Sep 16, 2016
Study completion Sep 16, 2016
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to collect the safety data of idarucizumab for patients treated with dabigatran who require rapid reversal of the anticoagulant effects of dabigatran in cases of uncontrolled or life-threatening bleeding or when emergency surgery or urgent procedures are required.
Conditions
- Hemorrhage
Interventions
idarucizumabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Drug-related Adverse EventsTime frame: from first drug administration until 5 days after last drug administration, up to 6 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fukuoka Tokushukai Medical Center
Fukuoka, Kasuga, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.